Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 13/20 | 0.66 |
| ▸ | CDK2 | P24941 | 7/20 | 0.57 |
| ▸ | CCNE1 | P24864 | 4/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12953954 | 0.94 | GSK3B (0.68) | GSK3BCDK2CCNE1MEN1LMNA | |
| SCHEMBL13120571 | 0.93 | GSK3B (0.66) | GSK3BCDK2CCNE1MEN1LMNA | |
| SCHEMBL13120612 | 0.93 | GSK3B (0.66) | GSK3BCDK2CCNE1MEN1LMNA | |
| SCHEMBL13120585 | 0.93 | GSK3B (0.66) | GSK3BCDK2CCNE1MEN1LMNA | |
| SCHEMBL12954427 | 0.93 | GSK3B (0.66) | GSK3BCDK2CCNE1MEN1LMNA | |
| SCHEMBL13120589 | 0.92 | GSK3B (0.64) | GSK3BCDK2CCNE1MEN1LMNA | |
| SCHEMBL13120579 | 0.92 | GSK3B (0.65) | GSK3BCDK2CCNE1MEN1LMNA | |
| SCHEMBL13120610 | 0.92 | GSK3B (0.65) | GSK3BCDK2CCNE1MEN1LMNA | |
| SCHEMBL13120603 | 0.91 | GSK3B (0.64) | GSK3BCDK2CCNE1MEN1LMNA | |
| SCHEMBL15576841 | 0.91 | GSK3B (0.67) | GSK3BCDK2CCNE1MEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070225270-A1 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2007-09-27 | — | — | US | disclosed |
| WO-2007044449-A2 | NOVEL PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS | SCHERING CORPORATION (US) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225270-A1 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | CDK2, CDKN1A, CDK1 | GSK3B 749/4885CDK2 1/4885CCNE1 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.